Merit Financial Group’s Moderna MRNA Stock Holding History

Merit Financial Group’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.77M	Buy	+25,205	New	+$1.3M	0.01%	804
2024 Q3	–	Sell	-2,154	Closed	-$256K	–	914
2024 Q2	$256K	Sell	2,154 -832	-28%	-$105K	0.01%	769
2024 Q1	$373K	Sell	2,986 -355	-11%	-$35.8K	0.01%	634
2023 Q4	$332K	Sell	3,341 -789	-19%	-$66.4K	0.01%	594
2023 Q3	$427K	Buy	4,130 +93	+2%	+$10.4K	0.01%	488
2023 Q2	$490K	Buy	4,037 +1,282	+47%	+$171K	0.02%	475
2023 Q1	$423K	Sell	2,755 -9,924	-78%	-$1.64M	0.02%	441
2022 Q4	$2.28M	Sell	12,679 -292	-2%	-$47.7K	0.08%	176
2022 Q3	$1.53M	Sell	12,971 -2,831	-18%	-$430K	0.07%	191
2022 Q2	$2.26M	Buy	15,802 +13,711	+656%	+$1.96M	0.07%	174
2022 Q1	$360K	Buy	2,091 +791	+61%	+$133K	0.02%	278
2021 Q4	$330K	Buy	1,300 +170	+15%	+$49.7K	0.03%	210
2021 Q3	$435K	Buy	1,130 +185	+20%	+$68.2K	0.05%	172
2021 Q2	$222K	Buy	+945	New	+$169K	0.02%	246

Other funds holding MRNA

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

MIM

Morningstar Investment Management Chicago, Illinois $1.62B AUM 13.96% 1-Year Est. Return

LAI

Legal Advantage Investments Los Altos Hills, California $285M AUM 18.63% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Merit Financial Group's MRNA Position: Q2 2026 in Review

Merit Financial Group opened a new position in Moderna (MRNA) in Q2 2026: 25,205 shares worth $1.77M. The stake represents 0.01% of the portfolio and ranks #804 among its holdings. This is a return to the name: Merit Financial Group previously reported a position in MRNA as recently as Q2 2024.

Merit Financial Group first reported a position in MRNA in Q2 2021 and has held it in 14 quarters since. The position peaked at $2.28M in Q4 2022. 144 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Merit Financial Group held 25,205 shares of Moderna worth $1.77M as of Q2 2026.
Moderna was a new Merit Financial Group position in Q2 2026.
Moderna made up 0.01% of Merit Financial Group's portfolio in Q2 2026, its #804 holding.
Merit Financial Group first reported a position in Moderna in Q2 2021 and has held it in 14 quarters since.
Merit Financial Group's Moderna position peaked at $2.28M in Q4 2022.
144 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.